Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 1Monoclonal Gammopathy of Undetermined Significance 1Hematologic Neoplasms 1Anemia, Aplastic 1

Interventions

Cyclophosphamide 23fludarabine phosphate 19Whole-Body Irradiation 17fludarabine 16Melphalan 16Tacrolimus 14Busulfan 14Peripheral Blood Stem Cell Transplantation 11Mycophenolic Acid 11Alemtuzumab 9Cyclosporine 7Methotrexate 6Antilymphocyte Serum 6thymoglobulin 4Stem Cell Transplantation 4Thiotepa 3Methylprednisolone 3Granulocyte Colony-Stimulating Factor 3Etoposide 3AP 1903 reagent 3sargramostim 2Transplantation 2Sirolimus 2Rituximab 2Mesna 2Influenza Vaccines 2Immunoenzyme Techniques 2Hematopoietic Stem Cell Transplantation 2Flow Cytometry 2Filgrastim 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anemia, Aplastic × Practice Guidelines as Topic × Classical hematology × Clear all
NCT04439006 2023-12-26

Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
10 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Aplastic, Monoclonal Gammopathy of Undetermined Significance, Myelodysplastic Syndromes, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡